We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/2/2023 12:11 | Meet someone who knows a bit about the tech. Said it’s a good idea, but could be up to 12 months before they sell anything as they have no details on a timeline to production | danmart2 | |
11/2/2023 10:26 | Perhaps one of the big companies will buy us out.. There might be a bidding war. That should be good for us. It might recoup us some of our money. | daijavu | |
10/2/2023 11:39 | Given how close they are to treating first patient, 2nd half of this year; and all the backers they have, and credibility of the science and the links to Cern etc, that they will be able to get majority of cash needed by bank loan/some other non-dilutive means. But much much will be a rights issue/placing and at what price? share price not being positive... | gerhart | |
09/2/2023 16:12 | I might consider buying back in if it gets to 1 or 2p. Just for the hell of it. | daijavu | |
02/2/2023 16:19 | I remember when this was around 10p previously and TW was saying short it to zero. They were in death spiral refinancing, issuing shares for cash at discount, and those shares repeatedly dumped driving price down. Then it was just a case of rinse and repeat. Then one day, they got a grip and came up with a new plan and the share price rocketed. So lets hope that can borrow a big chunk based on being so much further down the line, with a lot of solid scientific work already complete. | gerhart | |
20/1/2023 21:30 | Harley Street is still there, complete with all that's necessary for the clinic, created at the landlord's expense. All that's wanting is a company capable of developing the market and potential of LIGHT. | daijavu | |
20/1/2023 10:35 | Must have missed it. What happened to Harley street | waterloo01 | |
20/1/2023 10:27 | Yes a company with a market cap of £55m wants to raise £75m+ with no turnover and the only asset being a device with massive prospects but for which they have no orders. Lol Presumably the only taker would be a v wealthy individual who would want to do a deal with the directors but extinguish the interests of private investors. | twirl | |
19/1/2023 08:30 | So more dilutive share placings coming. Nothing new there. But at last they have now outlined the longer term funding issues. I wonder is there a large rights issue coming, even for the selected. Is that the real reason so many directors bought in the post-Christmas period. So that they have the more "rights" to a rights issue compliment and don't get diluted further. Hopefully, given how far down the road they are, that they will be able to raise most on secured loans etc. | gerhart | |
15/1/2023 15:12 | Pharma is a scam Caveat emptor | volsung | |
22/12/2022 17:29 | Daijavu>> Nice to hear from you. It is indeed a tragedy that a product with such potential is being held back by this BoD when they could have sold the rights etc to a large pharma that could afford to develop it at pace. That would with hindsight have provided a better return for investors. Instead we have been led up the garden path of Chinese hospitals and Harley St. and endless dilution. Fortunately I sold out at an uncomfortable loss years ago and have learn't a hard lesson. Turnover is King. | twirl | |
22/12/2022 12:58 | twirl. You and I share many years experience of AVO. None of it good. I get a very strong impression that we are seeing a repeat of past sorry events. The current AVO line is that they have multiple agreements and contracts and are very close to completion. So close, in fact, that it seems it will all come together next year. twirl. You will remember how many times over the years that AVO has claimed to be in precisely the same position they claim to be in now. And it has all gone up in smoke. New funds were raised, completion dates changed dramatically and all the contracts vanished as if they'd never been. Even the manufacturers ceased to be mentioned, only to be replaced a couple of years later by new ones. It's reached the sage now that I'm beginning to suspect that AVO might just be another GLOBO. Full of false promises with nothing to back them up. Either that or an incompetent BOD that is totally out of their depth and not to be relied on. | daijavu | |
13/12/2022 13:09 | I suppose the market is interpreting the 25p fund raise from "an existing institutional shareholder". If you don't cough up at an outrageous 25p we will go bust and you will lose your "investment" | twirl | |
24/10/2022 13:08 | Judging by todays share price action they are touting round for the price of the next fund raising that normally follows bullsh*t presentations to investors. | twirl | |
19/10/2022 11:32 | Did somebody say they were having an investor day? I have confidence that we will get there in the end, but I do want to know that we are moving as quickly as possible. Presumably Odey have done due diligence, which gives more confidence, and they will also be pressurizing management to move as fast as possible. | gclark | |
29/9/2022 09:42 | I have been waiting for this news and expecting a re-rating. Just bought some more. I see this as announcing the technology works and now it is about commissioning the room by a hospital for first patient treatments in h2 next year, yes, it sounds a long way off, but patience (not patients!) is a virtue. And I think this will start an increase in buyers getting their provisional orders in ... I can see the issue for the company being able to upscale manufacturing to meet demand, but having (too much) demand for your product is a nice thing to have in business, looking positively. | gclark | |
15/8/2022 03:54 | qipincha. Yes, facility not required. | dudishes | |
03/8/2022 09:09 | Does anyone remember AVO's massive reverse split of 2016? The share price had been hovering around 20p for quite a while when the BoD announced their brilliant plan to make the share price 'easier to understand'. They cut everyone's share holding by 25 times. so that if you owned, say, 1,000 shares before the reverse split, you suddenly owned just 40 shares after it. But the share price immediately went up to £5 a share so you didn't lose any money. Not at first. The BoD then went on to gradually increase the number of shares through fund raisings, causing massive dilutions that have brought the share price back down to around 20p. I wonder what they'll do next? | daijavu |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions